Dr Reddy’s Laboratories Ltd and Rheoscience, a subsidiary of Nordic Bioscience A/S, announced the headline results from the first phase-III study for their investigational agent, Balaglitazone. The study (Study 307) was a phase-III, randomized, double blind, parallel-group placebo- and active comparator-controlled clinical study to determine the efficacy and safety of balaglitazone.
The details can be read here.
No comments:
Post a Comment